We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

31 Oct 2018 - 02 Nov 2018
03 Nov 2018 - 07 Nov 2018
12 Nov 2018 - 15 Nov 2018

Virtual Model Set to Boost Drug Development Efforts

By BiotechDaily International staff writers
Posted on 27 Mar 2018
Print article
Image: A novel technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans is based on a microfluidic platform that connects engineered tissues from up to 10 organs (Photo courtesy of Felice Frankel).
Image: A novel technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans is based on a microfluidic platform that connects engineered tissues from up to 10 organs (Photo courtesy of Felice Frankel).
A novel "physiome-on-a-chip" platform is expected to aid drug developers by combining several "organ-on-a-chip" nodes into an in vitro model of a functioning organism.

Microphysiological systems (MPSs) are in vitro models that capture facets of in vivo organ function through use of specialized culture microenvironments, including three-dimensional matrices and microperfusion. To adapt MPS technology for purposes of drug development, investigators at the Massachusetts Institute of Technology (Cambridge, USA) developed a method to co-culture multiple different MPSs linked together physiologically on re-useable, open-system microfluidic platforms. Each MPS platform represented a different organ and was compatible with the quantitative study of a range of compounds, including lipophilic drugs.

The investigators adapted the physiome-on-a-chip platform from technology they had previously developed and commercialized through the biotechnology company CN BioInnovations (Welwyn Garden City, United Kingdom), The system incorporated several on-board pumps to control the flow of fluids between the "organs," on different nodes replicating the circulation of blood, immune cells, and proteins through the human body.

The investigators reported in the March 14, 2018, online edition of the journal Scientific Reports that they had created several versions of the chip, linking up to 10 organ types: liver, lung, gut, endometrium, brain, heart, pancreas, kidney, skin, and skeletal muscle. Each "organ" consisted of clusters of one million to two million cells.

"Animals do not represent people in all the facets that you need to develop drugs and understand disease," said senior author Dr. Linda Griffith, professor of biological and mechanical engineering at the Massachusetts Institute of Technology. "That is becoming more and more apparent as we look across all kinds of drugs. A lot of the time you do not see problems with a drug, particularly something that might be widely prescribed, until it goes on the market. Some of these effects are really hard to predict from animal models because the situations that lead to them are idiosyncratic. With our chip, you can distribute a drug and then look for the effects on other tissues and measure the exposure and how it is metabolized."

"An advantage of our platform is that we can scale it up or down and accommodate a lot of different configurations," said Dr. Griffith. "I think the field is going to go through a transition where we start to get more information out of a three-organ or four-organ system, and it will start to become cost-competitive because the information you are getting is so much more valuable."

Related Links:
Massachusetts Institute of Technology
CN BioInnovations


Print article

Channels

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2018 Globetech Media. All rights reserved.